Supplementary Tables and Figures from Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Supplementary Table S1 and Supplementary Figures S1-S3 - Supplementary Table S1: Characteristics of human triple-negative breast cancer cell lines. Supplementary Figure S1: Quantitation of protein expression in HC1806 and MDAMB231 cells following 72 hours of treatment in vitro. Supplementary Figure S2: Combined BYL719 and LEE011 induces anti-tumor immunity in AT3OVA mouse model of triple-negative breast cancer in vivo. Supplementary Figure S3: Immune checkpoint blockade in combination with BYL719 and LEE011 results in durable tumor regression in vivo.